Compare Inovio Pharmaceuticals Inc (INO) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Union Pacific Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Union Pacific Corporation trades at $278.34 (market cap $165.27B). The key difference: Union Pacific Corporation is far larger — about 1473.1× Inovio Pharmaceuticals Inc's market cap, and Union Pacific Corporation pays a 2.04% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Union Pacific Corporation for 105 Days on average.
| INO | UNP | |
|---|---|---|
Market Cap | $112.19M | $165.27B |
Volume | 3,201,278 | 1,474,117 |
Sector | Health | Industrials |
52-Week High | $2.65 | $310.62 |
52-Week Low | $0.66 | $216.37 |
Typical Hold Time | 43 Days | 105 Days |
Enterprise Value | $83.51M | $194.33B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
Union Pacific (UNP) trades at $278.34, up 1.33% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with 28.85% net margins and consistent earnings beats, while maintaining positive cash flow generation. Recent developments include deployment of battery-electric locomotives and progress on the Norfolk Southern combination, positioning the railroad for future growth.
The outlook remains positive with analyst consensus pointing to 19% upside potential to the $332.10 price target. Key opportunities include pricing power from high diesel costs shifting freight to rail, while risks center on merger uncertainty and fuel cost pressures on operating ratios.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
